Profile data is unavailable for this security.
About the company
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
- Revenue in USD (TTM)63.60m
- Net income in USD-19.04m
- Incorporated2003
- Employees203.00
- LocationExagen Inc1261 Liberty WayVISTA 92081United StatesUSA
- Phone+1 (760) 560-1501
- Fax+1 (302) 655-5049
- Websitehttps://exagen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exagen Inc | 63.60m | -19.04m | 75.01m | 203.00 | -- | 4.11 | -- | 1.18 | -0.9257 | -0.9257 | 3.14 | 0.8058 | 1.20 | -- | 6.21 | 313,295.60 | -35.78 | -31.53 | -44.92 | -35.82 | 59.86 | 56.16 | -29.94 | -53.16 | -- | -2.01 | 0.5911 | -- | 5.89 | 6.62 | 36.19 | -- | 5.03 | -- |
| DocGo Inc | 368.09m | -51.59m | 77.88m | 3.40k | -- | 0.2879 | -- | 0.2116 | -0.5213 | -0.5213 | 3.68 | 2.77 | 0.8685 | -- | 2.16 | 108,135.50 | -14.55 | -- | -19.45 | -- | 31.21 | -- | -16.75 | -- | -- | -- | 0.0599 | -- | -1.24 | -- | 191.50 | -- | -- | -- |
| Park Dental Partners Inc | 240.21m | 5.14m | 78.44m | -- | 15.25 | 204.26 | 5.45 | 0.3265 | 1.26 | 1.26 | 58.71 | 0.0939 | -- | -- | -- | -- | -- | -- | -- | -- | 16.20 | -- | 2.14 | -- | -- | 9.22 | 0.9701 | -- | 2.81 | -- | -10.76 | -- | -- | -- |
| American Well Corp | 249.33m | -95.70m | 91.53m | 562.00 | -- | 0.3857 | -- | 0.3671 | -5.95 | -5.95 | 15.53 | 14.34 | 0.6563 | 56.97 | 4.10 | 443,638.80 | -24.55 | -31.34 | -33.82 | -36.53 | 53.79 | 42.50 | -37.41 | -110.06 | 3.35 | -- | 0.00 | -- | -1.98 | 0.3289 | 54.02 | -- | -63.67 | -- |
| Biodesix Inc | 80.17m | -39.54m | 101.67m | 273.00 | -- | -- | -- | 1.27 | -5.36 | -5.36 | 10.85 | -0.2165 | 0.8375 | -- | 7.74 | 293,674.00 | -41.30 | -51.25 | -49.31 | -72.81 | 79.82 | 63.18 | -49.31 | -90.86 | -- | -4.37 | 1.04 | -- | 45.30 | 23.77 | 17.67 | -- | 19.43 | -- |
| Airsculpt Technologies Inc | 157.55m | -17.98m | 112.39m | 389.00 | -- | 1.37 | -- | 0.7133 | -0.2975 | -0.2975 | 2.64 | 1.32 | 0.7994 | -- | 50.58 | 405,023.10 | -9.13 | -0.9512 | -10.44 | -1.04 | 63.97 | 65.87 | -11.41 | -1.25 | -- | -0.6726 | 0.4094 | -- | -7.95 | 34.33 | -84.22 | -- | 25.84 | -- |
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 30 Sep 2025 | 1.70m | 7.49% |
| Balyasny Asset Management LPas of 30 Sep 2025 | 723.43k | 3.19% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 688.57k | 3.04% |
| Invesco Capital Management LLCas of 30 Sep 2025 | 675.19k | 2.98% |
| Silvercrest Asset Management Group LLCas of 30 Sep 2025 | 519.47k | 2.29% |
| Kennedy Capital Management LLCas of 31 Dec 2025 | 480.03k | 2.12% |
| Wexford Capital LPas of 31 Dec 2025 | 466.78k | 2.06% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 414.45k | 1.83% |
| Mink Brook Asset Management LLCas of 31 Dec 2025 | 353.73k | 1.56% |
| Millennium Management LLCas of 30 Sep 2025 | 247.17k | 1.09% |
